ATOSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:38):

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases...

Stats
本日の出来高	695 745
平均出来高	1.71M
時価総額	191.59M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.0700 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.37
ATR14	$0.00400 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Finn Jonathan	Buy	25 000	Common Stock
2024-03-09	Cigler Tessa	Buy	20 834	Stock Option (right to buy)
2024-03-09	Cigler Tessa	Buy	0
2023-11-15	Weaver Gregory L	Sell	50 000	Common Stock
2023-11-15	Finn Jonathan	Buy	62 500	Stock Option (right to buy)

INSIDER POWER
71.45
Last 98 transactions
Buy: 26 594 652 \| Sell: 4 017 362

ボリューム相関

長: -0.12 (neutral)

短: 0.32 (neutral)

Signal:(49.585) Neutral

Atossa Therapeutics Inc 相関

10 最も正の相関
SVAC	0.927
MEDS	0.901
TLGT	0.888
PAIC	0.879
DMAC	0.867
STCN	0.863
SGH	0.861
LFMDP	0.86
XBIT	0.86
APYX	0.859

10 最も負の相関
AMRB	-0.937
NETE	-0.916
LWAC	-0.884
MMAC	-0.883
SRAC	-0.882
LMRKN	-0.832
ENOB	-0.823
RAVN	-0.821
PAYS	-0.819
BLTE	-0.817

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Atossa Therapeutics Inc 相関 - 通貨/商品

-0.84
( strong negative )

-0.81
( strong negative )

0.00
( neutral )

0.69
( moderate )

Atossa Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-23 000.00 (0.00 %)
EPS:	$-0.240

FY	2023
収益:	$0
総利益:	$-23 000.00 (0.00 %)
EPS:	$-0.240

FY	2022
収益:	$0
総利益:	$-8 000.00 (0.00 %)
EPS:	$-0.210

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.180

Financial Reports:

No articles found.

Atossa Therapeutics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.